Directory · CH
Biotechnology Research in Switzerland
A register of firms and the professionals working at them in the Biotechnology Research sector based in Switzerland. Browse the public index, then filter or export on Kipplo.
Companies
522 on file
Basilea Pharmaceutica
Basilea is a commercial-stage biopharmaceutical company founded in and headquartered in the heart of the life sciences hub of Basel area, Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands: Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. In addition, we have several preclinical anti-infective assets in our portfolio. Basilea currently has about 150 employees and is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.
51 to 200 staff
Caris Life Sciences
Caris Life Sciences® (Caris) is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S, Europe, Asia and other international markets.
1001 to 5000 staff
Infors Ht
INFORS HT, a Swiss-based company, bringing 60 years of expertise to bioprocessing research and development. We specialize in bioreactors, incubator shakers, and bioprocess software, offering scalable solutions for microbial and animal cell cultures. With advanced monitoring, control, and data logging, we focus on parallel systems and deliver high-quality, flexible solutions while maintaining close customer relationships.
201 to 500 staff
Ac Immune
AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.
51 to 200 staff
Mindmaze
MindMaze is a global leader in digital neuro-therapeutics (DTx) solutions with a mission to accelerate the brain's ability to recover, learn and adapt. With over a decade of work at the intersection of neuroscience, bio-sensing, engineering, mixed reality and artificial intelligence, its healthcare division is addressing some of the most challenging problems in neurology, including stroke, Alzheimer disease and Parkinson disease, by creating the universal platform for brain health and recovery and unique digital therapeutic interventions. MindMaze's pioneering FDA cleared and CE marked neuro-digital therapeutics accelerate patients' recovery from many critical neurological conditions. Founded in 2012 by CEO Dr Tej Tadi, MindMaze is the first Swiss Unicorn with offices in Lausanne, Baltimore, London, Paris and Mumbai.
51 to 200 staff
Kuhner Shaker
Kuhner AG is the leading developer and manufacturer of shaking machines for the international market. Founded in 1949 by Mr Adolf Kühner, this family business is now led by his son Markus Kühner. From bench top shakers to large scale industrial shakers, Kuhner offers machines of the highest quality. We endeavour to understand your science and cultivation needs to ensure solutions accelerating your time to market and elevating your results. We commit to earning the trust of our clients and establishing relationships which will span decades. Alongside the core shaker business, Kuhner AG is also a distributor for premium brands of laboratory equipment in Switzerland.
51 to 200 staff
Ubc
United BioSource LLC (UBC) is the leading provider of evidence development solutions with expertise in uniting evidence and access. UBC helps biopharma mitigate risk, address product hurdles, and demonstrate safety, efficacy, and value under real-world conditions. Underpinned by our scientific expertise, data and analytics, and innovative technologies, we offer our customers flexible solutions generating the relevant real-world data necessary to make more informed decisions earlier, meet stakeholder requirements, and ultimately, drive better patient outcomes.
1001 to 5000 staff
Excellgene Sa
Looking for a trusted partner in the development of cell lines and manufacturing processes? Look no further. With over 20 years of experience, we specialize in high-yielding (5-14 g/L), GMP-ready, CHO, and HEK293 cell lines for the production of biologics, biosimilars, and gene therapy (AAV, Adenovirus). We have a proven track record of expressing all types of proteins, including bi-specific mAb, Fc-fusions, viral proteins, cytokines, and more. Our team of scientists is ready to support your project from start to finish, including process development, analytical methods, scale-up, tox-batches, and Master Cell Banking. At our company, we pride ourselves on our commitment to quality and customer satisfaction. Contact us today to see how we can help you achieve your goals and be your trusted partner in cell line and process development.
51 to 200 staff
Lunaphore A Bio-Techne Brand
Lunaphore Technologies S.A, a Bio-Techne brand, is a Swiss-based life sciences company founded in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. Community guidelines available here: https://link.lunaphore.com/guidelines
51 to 200 staff
Moonlake Immunotherapeutics Nasdaq Mltx
MoonLake Immunotherapeutics AG is a clinical-stage biopharmaceutical company leveraging revolutionary Nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
11 to 50 staff
Packgene Biotech, Inc
PackGene is a world-leading AAV vector packaging CRO and CDMO. Founded in Massachusetts, USA, PackGene now has offices in Boston, Houston and Zurich. We work with customers to support gene therapy programs from early-stage R&D, preclinical development, to IND studies. Our mission is to accelerate gene therapy product development by providing an integrated one-stop solution including plasmid, viral vector, fill-finish and QC analytical services for the gene therapy industry.
201 to 500 staff
Selexis Sa
KBI Biopharma and Selexis SA are consolidating operations as one organization under the KBI Biopharma name. This streamlined approach supports customers in accelerating drug development and manufacturing, creating greater flexibility, efficiencies, and a simplified partner experience. You can follow us on the KBI Biopharma page to stay up-to-date on the latest news, events, and happenings.
1001 to 5000 staff
Cutiss Ag
CUTISS is a late-stage clinical TechBio company and the only one transforming skin surgery and advanced dermatology with revolutionary skin tissue therapeutics. We are developing the first BIO personalized and automated skin tissue therapy for patients requiring skin surgery for a large spectrum of indications- from severe burns to reconstructive and aesthetic procedures. Our lead product denovoSkin™ is a first-in-class, bioengineered, personalized skin tissue therapy designed to improve patient outcomes and redefine the standard of care in skin surgery. Currently in Phase 3 clinical trials in the European Union, it has Orphan Drug Designation for the treatment of burns from Swissmedic, the EMA, and the US FDA. CUTISS is also pioneering the TECH automation of skin tissue bioengineering, developing the world’s first machine capable of fully automating the manufacturing process. This breakthrough ensures scalability, accessibility and cost-efficiency, and supports attractive unit economics. Our proprietary TECHBIO platform offers growth opportunities in other areas of regenerative medicine, from space research to non-healthcare applications (tissues for industry). Established in 2017, CUTISS is a spin-off from University of Zurich (UZH) and University Children’s Hospital. Headquartered at the Bio-Technopark in Zurich, CUTISS won the Top 100 Swiss Startup Award 2020, and has raised over $90 million from private investors, family offices and public bodies.
11 to 50 staff
Cytosurge
Cytosurge develops innovative research solutions using its proprietary FluidFM® technology for precise single-cell manipulation thereby fostering advancements in understanding cellular processes such as the ones that drive cancer. With the FluidFM OMNIUM platform, single-cell extracts, or “biopsies” can be taken from living cells, enabling live-sequencing and temporal transcriptomics analysis. Additionally, the CellEDIT Service provides high-quality genetically engineered cell lines through intra-nuclear injections of CRISPR RNPs. Cytosurge's vision is to unlock novel cures by translating next-generation genetic designs into living cells, thereby enabling longer and healthier lives through precision gene engineering. The Company aims to implement advanced genetically engineered cell lines that bring next-generation therapies to fruition, bridging the gap between genetic design tools and manufacturing, and empowering genetic engineers to realize their visionary concepts.#FluidFM #AFM #mRNA #scRNAseq #LiveSeq #Transcriptomics #Genomics #CellEDIT #CRISPR #GeneEditing #GeneEngineering #CRISPRGeneEditing #GeneticEngineering #CellLineDevelopment #DNAmodifications
11 to 50 staff
Socorex Isba Sa
Socorex Isba SA is a reputable Swiss manufacturer of precision dosing instruments. Thanks to a high technical know-how, to the professionalism of its teams and to a healthy management of its growth along the past 60 years, Socorex is now a recognized player for liquid handling instruments for the laboratory and automatic syringes for serial animal injections.
11 to 50 staff
3brain Ag
3Brain developed and distributes the world’s first commercial CMOS-based high-resolution Microelectrode Array (MEA), a Biosensor integrating thousands of tiny electrical sensors in a small area. Our Biosensor allows non-invasive (in vitro) investigations of electrogenic cells, such as neurons, cardiac and muscle cells. The technology can be used to investigate electroactive cells' fundamental properties (e.g, neural code for learning and memory), to study and find new treatments to different types of diseases (e.g. Alzheimer and epilepsy) and to assess compounds/chemical toxicity.
11 to 50 staff
Evolva
At Evolva we believe in applying technology platforms, such as fermentation, to help resolve sourcing bottlenecks in nature. These enable us to provide products that can contribute to health, wellbeing and sensory enjoyment. We research, develop and commercialize high quality, affordable, ready-to-formulate ingredients that are based on nature and are available at all times, in any quantity. With around 55 employees from 15 nationalities we promote an interdisciplinary and inclusive working environment.
51 to 200 staff
Hedera Dx
Liquid biopsies provide better therapy options for more patients. Hedera Dx is on a mission to provide the next billion people with access to modern cancer care. We specialize in clinic-ready, NGS-based liquid biopsies that enable non-invasive diagnosis, timely treatment selection, and longitudinal disease monitoring. Our culture is based on thinking different, modern and human, fostering a dynamic and innovative work environment. Join us on hederadx.com to learn more!
11 to 50 staff
Hse Ag
HSE•AG: Engineering Precision for Life Science Innovation At HSE•AG, we empower breakthrough discoveries in life science and diagnostics by delivering tailored, high-performance engineering solutions. From concept to market, we partner with leading companies to transform complex biological workflows into scalable, automated systems. Our Expertise Includes- Laboratory automation and system integration - OEM product development and industrialization - Mechanical and software engineering - Instruments, software and consumable development - Life cycle and risk management - Application-driven design and concepts We bridge biological insight with engineering excellence, designing technologies that accelerate discovery, improve reproducibility, and streamline diagnostics. Our solutions are optimized for real-world use in research labs, diagnostic settings, and manufacturing environments. At HSE•AG, we don’t just solve engineering problems—we help you create measurable impact. Let’s shape the future of life sciences, together.
51 to 200 staff
Maxwell Biosystems
Founded in September 2016 as an ETH Zürich spin-off, MaxWell Biosystems is a technology leader providing instrumentation and solutions to boost scientific research and development in neurosciences, stem cell and tissue engineering, ophthalmology, and other fields involving electrogenic cells. MaxOne (single-well) and MaxTwo (multi-well) are easy-to-use systems that equip scientists with the ability to record electrical signals of neurons in in-vitro 2D and 3D models at network, cellular, and subcellular levels. MaxWell Biosystems’ main goal is to be a trusted partner to all users and collaborators, for a greater cause, of advancing scientific breakthroughs and for achieving faster and more effective drug discovery, through our products, solutions, and expertise.
51 to 200 staff
Monte Rosa Therapeutics
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN™ discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs.
51 to 200 staff
Polpharma Biologics
Polpharma Biologics is a biopharmaceutical company headquartered in Switzerland that develops, manufactures and commercializes biosimilars for global markets. We manage the entire value chain: from product selection and investment allocation, through program execution to asset monetization, ensuring fast progress from idea to launch. Our international team of senior experts has proven experience in program leadership, regulatory strategy, clinical oversight, CMC integration, device development and quality. Working with trusted CDMOs, we deliver end-to-end biosimilars, from cell line to finished product, across a range of major therapeutic areas. Our commercial partners bring these medicines to patients worldwide. Our mission is simple: to accelerate access to biologics. To fulfill that mission, we maintain a robust, expanding pipeline of biosimilars in development.
1001 to 5000 staff
Reploid
REPLOID is a globally active, publicly traded biotechnology company that converts organic waste (such as food waste) into high-quality proteins, fats, and fertilizers by breeding black soldier flies (Hermetia illucens) in order to promote industrial and regional circular economies, reduce emissions, and conserve resources by building and selling decentralized, highly automated modular insect farms. The goals are a global net-zero strategy, the circular and sustainable recycling of waste into valuable raw materials for animal feed, especially for dogs, cats, chickens, and fish, as well as high-quality hybrid biofertilizers that are produced and sold in collaboration with partners.
51 to 200 staff
Rgcc International
At RGCC, we are at the forefront of revolutionizing healthcare through personalized solutions for cancer and chronic diseases. Our commitment is global, aiming to provide personalized, accessible, diagnostic and therapeutic options to patients worldwide. Explore our innovative range of tests and therapies meticulously tailored for each patient's unique needs at rgcc-international.com.
51 to 200 staff
